Understanding donor characteristics to improve allogeneic cell therapy outcomes for all
On demand

Understanding donor characteristics to improve allogeneic cell therapy outcomes for all

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Understanding donor characteristics to improve allogeneic cell therapy outcomes for all

Join us for an in-depth discussion of efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes. This webinar will also focus on equity within the cell and gene therapy space and how reported characteristics like race and ethnicity can impact data quality.

Attend this webinar to discover more about:

  • How proven transplant infrastructure can assist in the delivery of cell and gene therapies
  • The complexity of HLA in cell selection (including reported race, ethnicity, and the impact on data quality)
  • The use of machine learning in informing cell/source selection
Abeer Madbouly
Abeer Madbouly
Principal Bioinformatics Scientist, Be The Match

Abeer Madbouly has over 15 years of experience in bioinformatics. Her role involves improving the donor/patient tissue matching process by developing better validation methods, more innovative matching, better collection of donor and recipient race/ethnicity/ancestry information and diversified population genetics analyses. She investigates multiple gene systems with the goal of improving post-transplant event-free survival.

Dr. Madbouly joined the BTM Bioinformatics team in 2010. She earned a Doctor of Philosophy in Electrical and Computer Engineering from the University of Miami, Coral Gables, FL. She currently serves as adjunct assistant professor at the University of Minnesota, Bioinformatics and Computational Biology program and the Chair of the Science and Technology Initiatives Committee at the American Society of Histocompatibility and Immunogenetics.

Martin Maiers
Martin Maiers
Vice President, Research, Be The Match

Martin Maiers is the Vice President of Biomedical Informatics Research at the Center for Blood and Marrow Transplant Research and National Marrow Donor Program/Be The Match Registry where he has worked for 25 years. He heads a “dry lab” research program focused on HLA and KIR data standards, matching and algorithm development. With his team he has developed a number of tools and methods for searching large donor registries with missing or partial information to identify suitable hematopoietic stem cell donors. In particular he has lead a series of population HLA haplotype frequency studies that drive the operation of the Be The Match Registry algorithm: HapLogic. He holds a degree in Mathematics from the University of Wisconsin and earned a Masters Degree in “Biomedical Informatics and Computational Biology” from the University of Minnesota. He is a Councillor to the International Histocompatibility and Immunogenetics Workshop and is also a member of the WHO Nomenclature Committee for Factors of the HLA System.

Stephen Sullivan
Stephen Sullivan
Managing Director, Lindville Bio

Dr Sullivan is the Managing Director of Lindville Bio, an ATMP consultancy service specializing in the scalable manufacture of Pluripotent Stem Cells (PSC/iPSC) and therapeutic development therefrom.

Dr Sullivan initially earned his PhD at the Roslin Institute (Edinburgh), under Professor Ian Wilmut and Dr Jim McWhir, becoming one of the first researchers in Europe to culture human embryonic stem cells. His work focused on pluripotency induction in human somatic cells.

Thereafter, Dr Sullivan worked as a Research Fellow at the University of Cambridge, Harvard University, and UCSD deepening his expertise of other human stem cell types (including induced pluripotent stem cells) and their medical applications.

Thereafter, he also worked for Novartis, dealing with clinical trial management and compliance, to better understand manufacturing, logistic, and regulatory challenges to bringing new therapeutics to market and earned an MBA at Trinity College Dublin focusing on risk mitigation during AMTP development. With more than 20 years’ experience in the ATMP space, he focuses on the development and translation of pluripotent and induced-pluripotent stem cell therapeutics to the clinic.